

Clinical trials of intensive blood pressure control for hypertension in all type of patients

TrialResults-center www.trialresultscenter.org

1 Treatment blood pressure target

Trial	Treatments	Patients	Trials design and methods
more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie			
PAST-BP , 2015 n=NA	-	-	
Wei , 2013 n=NA follow-up: 4 years (mean)	BP <=140/90 mm Hg versus BP <=150/90 mm Hg	Chinese hypertensive patients older than 70 years	Parallel groups China
SPS3 , 2013 [NCT00059306.] n=NA follow-up:	less than 130 mm Hg versus 130-149 mm Hg	patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions	Parallel groups open-label
HOMED-BP , 2012 n=NA follow-up: 5.3 years (median)	tight control (<125/<80 mm Hg (TC)) of HBP versus usual control (125-134/80-84 mm Hg (UC))	with an untreated systolic/diastolic HBP of 135-179/85-119 mm Hg	Parallel groups
VANLISH , 2010 n=NA follow-up: 3.07 years (median)	strict blood pressure control (<140 mm Hg) versus moderate blood pressure control (>or =140 mm Hg to <150 mm Hg)	patients aged 70 to 84 years with isolated systolic hypertension (sitting blood pressure 160 to 199 mm Hg)	Parallel groups open-label
JATOS , 2008 n=2212/2206 follow-up:	strict treatment to maintain systolic blood pressure below 140 mmHg versus mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg	elderly hypertensive patients with essential hypertension (65-85 years old, with a pretreatment systolic blood pressure of above 160 mmHg)	Parallel groups open-label
UKPDS-HDS , 1998 n=758/390 follow-up: 8.4 years	blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) versus less tight control aiming at a blood pressure of <180/105 mm Hg	patients with type 2 diabetes	Parallel groups open-label UK
SPRINT , 2015 [NCT01206062] n=4678/4683 follow-up:	target of 120 mm Hg versus target of 140 mm Hg	high-risk hypertensive adults 50 years of age and older with one additional cardiovascular risk factor or preexisting kidney disease	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
Cardio-Sis , 2009 [NCT00421863] n=558/553 follow-up: 2 years	tighter control of systolic BP with a goal of <130 mm Hg versus usual control, with a goal of <140 mm Hg	nondiabetic patients with hypertension and with SBP of 150 mm Hg or higher confirmed at two different times	Parallel groups open Italy
AASK , 2002 n=540/554 follow-up: (range 3-6.4y)	arterial pressure goal of 92 mm Hg or lower versus usual mean arterial pressure goal of 102 to 107 mm Hg/pj	African-Americans, with diastolic blood pressure higher than 94mmHg and a glomerular filtration rate between 20 and 65 ml/min per 1.73 m ²	Parallel groups open USA
ABCD target (H) , 2000 n=237/233 follow-up: 5 year	intensive treatment with a diastolic blood pressure goal of 75 mmHg versus moderate treatment with a diastolic blood pressure goal of 80-89 mmHg	diabetes patients with DBP \geq 90 mmHg	Parallel groups open
ABCD target (N) , 2002 n=237/243 follow-up:	intensive treatment (diastolic blood pressure decrease of 10 mmHg below baseline DBP) versus moderate treatment (diastolic blood pressure goal of 80-89 mmHg)	diabetes patients with diastolic blood pressure between 80 and 89mmHg	Parallel groups open
HOT , 1994 n=12526/6264 follow-up: 3.8 y	less or equal than 85 mmHg, or less or equal than 80 mmHg versus less or equal than 90 mmHg	patients with diastolic blood pressure between 100 mmHg and 115 mmHg	Factorial plan open 26 countries
REIN-2 , 2005 n=169/169 follow-up: 36 months	intensified (systolic/diastolic <130/80 mm Hg) blood-pressure control versus conventional (diastolic <90 mm Hg) blood-pressure control	patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril	open
MDRD , 1994 n=840 follow-up: 2.2 y	low target blood pressure (mean arterial pressure <92 mm Hg) versus usual target blood pressure (mean arterial pressure <107 mm Hg)	patients with predominantly nondiabetic kidney disease and a glomerular filtration rate of 13 to 55 mL/min per 1.73 m ²	open
Toto , 1995 n=42/35 follow-up:	strict blood pressure control (DBP 65 to 80 mm Hg) versus usual blood pressure control (DBP 85 to 95 mm Hg)	non-diabetic patients (age 25 to 73) with long-standing hypertension (DBP \geq 95 mm Hg), chronic renal insufficiency (GFR \leq 70 mL/min/1.73 m ²) and a normal urine sediment	open
ACCORD blood pressure , 2008 [NCT00000620] n=2362/2371 follow-up: 4.7y	intensive therapy, targeting a systolic pressure of less than 120 mm Hg versus standard therapy, targeting a systolic pressure of less than 140 mm Hg	patients with a median glycated hemoglobin level of 8.1% at high risk for cardiovascular events	Factorial plan open USA, Canada
ESH-CHL-SHOT <i>ongoing</i> [NCT01563731] n=NA	-	-	

References

PAST-BP, 2015:

Wei, 2013:

Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, Wang J Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. *J Clin Hypertens* (Greenwich) 2013;15:420-7 [23730991] [10.1111/jch.12094](#)

SPS3, 2013:

Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet* 2013;382:507-15 [23726159] [10.1016/S0140-6736\(13\)60852-1](#)

HOMED-BP, 2012:

Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. *Hypertens Res* 2012;35:1102-10 [22895063] [10.1038/hr.2012.125](#)

VANLISH, 2010:

Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. *Hypertension* 2010;56:196-202 [20530299] [10.1161/HYPERTENSIONAHA.109.146035](#)

JATOS, 2008:

Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res* 2008;31:2115-27 [19139601] [10.1291/hypres.31.2115](#)

UKPDS-HDS, 1998:

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703-13 [9732337]

SPRINT, 2015:

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med* 2015 Nov 9;: [26551272] [10.1056/NEJMoa1511939](#)

Cardio-Sis, 2009:

Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. *Lancet* 2009;374:525-33 [19683638]

AASK, 2002:

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002;288:2421-31 [12435255]

ABCD target (H) , 2000:

Estacio RO, Jeffers BW, Gifford N, Schrier RW Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes Care* 2000;23 Suppl 2:B54-64 [10860192]

ABCD target (N) , 2002:

Schrier RW, Estacio RO, Esler A, Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002;61:1086-97 [11849464] [10.1046/j.1523-1755.2002.00213.x](#)

HOT, 1994:

Hansson L, Zanchetti A, Carruthers SG, Dahlb B, Elmfeldt D, Julius S, Mnard J, Rahn KH, Wedel H, Westerling S Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *HOT Study Group. Lancet* 1998;351:1755-62 [9635947]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. *Blood Press* 1997;6:313-7 [9360003]

Hansson L, Zanchetti A The Hypertension Optimal Treatment (HOT) Study—patient characteristics: randomization, risk profiles, and early blood pressure results. *Blood Press* 1994;3:322-7 [7866597]

Zanchetti A, Hansson L, Dahlf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. *J Hypertens* 2001;19:1149-59 [[11403365](#)]

REIN-2, 2005:

Ruggenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005;365:939-46 [[15766995](#)] [10.1016/S0140-6736\(05\)71082-5](#)

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703-13 [[9732337](#)]

MDRD, 1994:

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994;330:877-84 [[8114857](#)]

Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Parandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension* 1997;29:641-50 [[9040451](#)]

Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995;123:754-62 [[7574193](#)]

Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med* 2005;142:342-51 [[15738453](#)]

Toto, 1995:

Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. *Kidney Int* 1995;48:851-9 [[7474675](#)]

ACCORD blood pressure, 2008:

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59 [[18539917](#)] [10.1056/NEJMoa0802743](#)

Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99:44i-55i [[17599425](#)] [10.1016/j.amjcard.2007.03.005](#)

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *N Engl J Med* 2010 Mar 14;: [[20228401](#)] [10.1056/NEJMoa1001286](#)

ESH-CHL-SHOT, :

Entry terms: Lovenox, Clexane, Sectral, Monitan, Rhotral, Neptal, Veroshpiron, Verospirone, Spiractin, Spirobeta, Spirogamma, Spirolang, Spiro-Isis, Spirono Isis, Spironone, Spirospare, Verospiron, Aldactone, Aldactone A, Aquareduct, duraspiron, Espironolactona Alter, Espironolactona Mundogen, Flumach, Frumikal, Jenaspiron, Novo-Spiroton, Novo Spiroton, NovoSpiroton, Practon, Spiro L.U.T., spiro von ct, , Amiobeta, Cordarone, Cordarex, Amiodarex, Kordaron, Trangorex, Amiodarona, Amiohexal, Braxan, Corbionax, Ortacrone, Rytmarone, Tachydaron, Aratac, BMS 562247, BMS562247, BMS-562247, Eliquis, , TRK 100, TRK-100, beraprost sodium, , Befibrat, Beza-Lande, Beza Lande, BezaLande, Beza-Puren, Beza Puren, BezaPuren, Bezabeta, Bezacur, Bezafibrat PB, Bezafisal, Bezalip, Eulitop, Bezamerck, durabezur, BM-15.075, BM 15.075, BM15.075, Cedur, Difaterol, Bfizal, Lipox, Reducterol, Regadrin B, Sklerofibrat, Solibay, Azufibrat, , fluorescent bezafibrate, DNS-X, , Bisoprolol Hydrochloride, Bisoprolol Methanesulfonate Salt, EMD-33512, EMD 33512, EMD33512, CL-297939, CL 297939, CL297939, Concor, Bisoprolol Fumarate, , Hirulog-1 Hirulog Angiomax, bucindolol, bucindolol hydrochloride, MJ 13105, , candesartan cilexetil, TCV 116, TCV-116, Atacand, Blopress, Kenzen, Amias, Parapres, candesartan, CV 11974, CV11974, CV-11974, , carvedilol, Querto, Coreg, Dilatrend, Kredex, Coropres, Eucardic, BM 14190, BM-14190, Baycol, Lipobay, Cholestyramine Resin, Colestyramin, Colestyramins, Colestyramine, Colestyramines, Cholestyramine, Cholestyramines, Questran, Questrans, Quantalan, Quantalans, Cuemid, Cuemids, MK-135, MK 135, MK135, , Plavix, Iscover, Colestipol, Colestipol Hydrochloride, Colestipol HCl, Colestid, , Pradaxa, Pradax, Hydralazine, Hydrallazin, Hydrazinophthalazine, Aprestin, Nepresol, Hydralazine mono-Hydrochloride, Hydralazine mono Hydrochloride, Apresoline, Apresoline, Hydralazine Hydrochloride, , idraparinux, , Aprovel, Avapro, Karvea, ivabradine, Corlanor, Procorolan, S 16257-2, S-16257-2, S-16260-2, S 16260-2, S 16257, S-16257, , SUN

9216, SUN9216, SUN-9216, lanotepase, , Lisinopril, Lysinopril, Zestril, Prinivil, MK-521, , Losartan, Cozaar, MK-954, MK 954, MK954, DuP-753, DuP 753, DuP753, Losartan Potassium, Losartan Monopotassium Salt, , Lovastatin, Mevinolin, Monacolin K, 6-Methylcompactin, 6 Methylcompactin, MK-803, MK 803, MK803, Mevacor, , Metoprolol, Beloc-Duriles, Beloc Duriles, BelocDuriles, Betalok, Spesicor, Spesikor, H 93-26, H 93 26, H 9326, Lopressor, Metoprolol Tartrate, Seloken, Betaloc, Betaloc-Astra, Betaloc Astra, BetalocAstra, CGP-2175, CGP 2175, CGP2175, , nebivolol, nebivolol hydrochloride, Silostar, Nebilet, Lobivon, R 67555, R-67555, , Niacin, Nicotinic Acid, 3-Pyridinecarboxylic Acid, 3 Pyridinecarboxylic Acid, Induracin, Nicamin, Nico-400, Nico 400, Nico400, Nicobid, Nicocap, Nicolar, Nicotinate, Wampocap, Enduracin, Lithium Nicotinate, SQ-14534, SQ 14534, SQ14534, SQ-14225, SQ 14225, SQ14225, Capoten, Lopirin, , dipyridamole monoacetate, dipyridamol monoacetate, , Digoxin, Digacin, Digitek, Digoregen, Lanoxin, Lanoxin-PG, Lanoxin PG, Lenoxin, Digoxine Nativelle, Hemigoxine Nativelle, Dilanacin, Lanacordin, Lanicor, Lanoxicaps, Mapluxin, Digoxina Boehringer, , Dicumarol, Dicoumarol, Bishydroxycoumarin, Dicoumarin, , CYPHER, TAXUS, Promus, Xience, Biomatrix, Nobori, Endeavor, Drug-Eluting Stents, Drug Eluting Stents, Drug-Eluting Stent, Drug-Coated Stents, Drug Coated Stents, Drug-Coated Stent, , Multaq, Zetia, Ezetrol, Felodipine, Felo Biochemie, Felo-Puren, Felo Puren, Felobeta, Felocor, Felodipin 1A Pharma, Felodipin AbZ, Felodipin AL, Felodipin AZU, Felodipin dura, Felodur, Felogamma, Fensel, H 154-82, H 154 82, H 15482, Plendil, Flodil, Modip, Renedil, Munobal, Felodipin Heumann, Felodipin Stada, felodipin von ct, Felodipin-ratiopharm, Felodipin ratiopharm, Perfudal, Agon, , Procetofen, Flecainide, Flecatab, Flecainide Acetate, Flecainide Monoacetate, R818, Tambocor, Apocard, Flcane, Flecadura, Flecainid-Isis, Flecainid Isis, , Fish Oils, Fish Liver Oils, , fluvastatin, fluindostatin, Lescol, XU 62-320, XU-62320, XU 62320, fluvastatin sodium, fluvastatin sodium salt, , Quixidar, Arixtra, Fosinopril, Fosenopril, Monopril, Staril, Fosinorm, Newace, Hiperlex, Fozitec, Fosinil, Fositens, Dynacil, Tenso Stop, Tensocardil, Fosinopril Sodium, SQ-28555, SQ 28555, SQ28555, , Nadroparin, Nadroparine, Nadroparin Calcium, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , Furosemide, Frusemide, Fursemide, Frusemid, Furanthril, Furantral, Salix (brand of furosemide), Furosemide Monosodium Salt, Fusid, Lasix, Errolon, Furosemide Monohydrochloride, , Gemfibrozil, Gemfibrosil, Bolutol, CI-719, CI 719, CI719, DBL Gemfibrozil, Trialmin, Decrelip, Gemfi 1A Pharma, Gemfibrozilo Ur, Gemhexal, Gen-Gemfibrozil, Gen Gemfibrozil, GenGemfibrozil, GenRX Gemfibrozil, Healthsense Gemfibrozil, Jezil, Lipazil, Lipox Gemfi, Litarek, Lopid, Lopid R, Lipur, Pilder, SBPA Gemfibrozil, Apo-Gemfibrozil, Apo Gemfibrozil, ApoGemfibrozil, Ausgem, , Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , Labetalol, Labetolol, Albetol, Apo-Labetalol, Apo Labetalol, ApoLabetalol, Dilevalol, Normodyne, Presolol, SCH-19927, SCH 19927, SCH19927, Trandate, AH-5158, AH 5158, AH5158, Labetalol Hydrochloride, , Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , Nicardipine, Cardene SR, Dagan, Flusemide, Lecibril, Lincil, Loxen, Lucenfal, Nicardipine Hydrochloride, Nicardipine LA, Nicardipino Ratiopharm, Nicardipino Seid, Perdipine, Ridene, Y-93, Y 93, Y93, Cardene I.V., Cardene, Vasonase, Antagonil, , Nicorandil, 2-Nicotinamidoethyl Nitrate, 2 Nicotinamidoethyl Nitrate, 2-Nicotinamidethyl Nitrate, 2 Nicotinamidethyl Nitrate, SG-75, SG 75, SG75, Ikorel, Adancor, Dancor, , Nifedipine, Adalat, Bay-1040, Bay 1040, Bay1040, BAY-a-1040, BAY a 1040, BAYa1040, Procardia XL, Nifedipine-GTIS, Nifedipine GTIS, Corinfar, Korinfar, Fenigidin, Nifangin, Nifedipine Monohydrochloride, Procardia, Vascard, Cordipin, Cordipine, , Nitroglycerin, Glyceryl Trinitrate, Nitrolan, Nitrostat, Perlinganit, Susadrin, Sustac, Sustak, Sustonit, Transderm Nitro, Tridil, Trinitrin, Trinitrolong, Anginine, Dynamite, Gilustenon, Nitrangin, Nitro-Bid, Nitro Bid, NitroBid, Nitro-Dur, Nitro Dur, NitroDur, Nitrocard, Nitroderm, Nitroderm TTS, Nitroglyn, Nitrol, Nitrong, Nitrospan, , omapatrilat, Vanlev, BMS 186716, BMS-186716, , Omacor, Lovaza, omega-3 ethyl ester 90, P-OM3 adjunct, , Logiparin, LHN-1, , orlistat, tetrahydrolipstatin, THLP, Alli, Xenical, , Pentoxifylline, Oxpentifylline, BL-191, BL 191, BL191, Trental, Torental, Agapurin, Pentoxil, , Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine, , Actos, Practolol, ICI-50172, ICI 50172, ICI50172, Dalzic, Eralzdin Practolol, , Pravastatin, Eptastatin, Liplat, RMS-431, RMS 431, RMS431, SQ-31000, SQ 31000, SQ31000, Vasten, Bristacol, CS-514, CS 514, CS514, Lipemol, Prareduct, Mevalotin, Pravachol, Elisor, Selektine, Pravacol, Pravasin, Lipostat, , prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient, Probuocol, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir, , Propranolol, Propanolol, Avlocardyl, AY-20694, AY 20694, AY20694, Betadren, Dexpropranolol, Inderal, Obsidan, Obzidan, Propranolol Hydrochloride, Rexigen, Anaprilin, Anapriline, Dociton, , Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285, , rimonabant, SR141716, SR 141716, Acomplia, Zimulti, SR 141716A, SR141716A, SR-141716A, , Xarelto, BAY 59-7939, , Avandia, Crestor, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase,

Rescupase, A-74187, , Zocor, Darob, MJ-1999, MJ 1999, MJ1999, , telmisartan, Micardis, BIBR 277, BIBR-277, Pritor, , tenecteplase, Metalyse, TNKase, Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid, , Timolol, Timoptic, Timoptol, Timolol Hemihydrate, Timacar, Timolol Maleate, MK-950, MK 950, MK950, Optimol, Blocadren, , tinzaparin, tinzaparin sodium, Innohep, tirofiban, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Aggrastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462, , tolvaptan, OPC 41061, OPC-41061, Samsca, , topiramate, Topamax, Epitomax, McN 4853, McN-4853, , trandolapril, Odrik, Udrik, RU 44570, RU44570, RU-44570, Mavik, Gopten, triflusal, Disgren, Centrophne, Vastarel, Idaptan, Trimetazidine Irex, Vasartel, Trimetazidine Dihydrochloride, , Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, , valsartan, Diovan, Tareg, KalpressMiten, Provas, Vals, valsartan, CGP 48933, Nisis, Aventis brand of valsartan, , Verapamil, Iproveratril, Cordilox, Dexverapamil, Falicard, Izoptin, Isoptine, Isoptin, Lekoptin, Verapamil Hydrochloride, Calan, Finoptin, , vesnarinone, OPC 8212, OPC-8212, , Xamoterol, Corwin, ICI-118587, ICI 118587, ICI118587, Xamoterol Fumarate, Xamoterol Hemifumarate, Xamoterol Monohydrobromide, Xamoterol Monohydrochloride, Xamtol, Carwin, Xamoterol Maleate (2:1), , ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95, , Glucotrol, Warfarin, Coumadine, Apo-Warfarin, Gen-Warfarin, Warfant, Coumadin, Marevan, Warfarin Potassium, Warfarin Sodium, Aldocumar, Tedicumar, , reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium, , Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Rytmogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecofen, , nateglinide, nate-glinide, senaglinide, IPCCPA, AY 4166, AY-4166, DJN 608, Starsis, Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , Bay K 5552, , Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin, , Integrilin, Integrelin, reteplase, Retavase, Rapilysin, Betaxolol, SL-75212, SL 75212, SL75212, Betoptic, Betoptima, Betaxolol, Oxodal, ALO-1401-02, ALO 1401 02, ALO140102, Betaxolol, Lipitor, torcetrapib, CP 529414, CP529414, CP-529414, , CYPHER, , XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, Endeavour, Medtronic Endeavour, albiglutide, , liraglutide, victoza, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR, , sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431, , Acenocoumarol, Nicoumalone, Acenocoumarin, Synthrome, Synthrom, Syncoumar, Syncumar, Sinkumar, Sintrom, Mini-Sintrom, Mini Sintrom, MiniSintrom, , Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , Bepidil Monohydrochloride, Vascor, Bedapin, CERM-1978, CERM 1978, CERM1978, 1978-CERM, 1978 CERM, 1978CERM, Cordium, Unicordium, Bepadin, , Ethyl Chlorophenoxyisobutyrate, Atromid, Atromid S, Miscleron, Miskleron, Athromidin, , elinogrel, PRT 060128, PRT060128, PRT-060128, , Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natrecor, , Phenindione, Phenylindanedione, Phenylene, Pindione, Fenilin, Dindevan, , repa-glinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW, , Brilique, Brilinta, AZD 6140, AZD6140, AZD-6140, zofenopril, Zofenil, Zofil, SQ 26900, SQ-26900, SQ 26991, SQ-26991, , SQ 26703, zofenopril-SH, zofenopril-SH cpd with arginine, , MK 0859, MK0859, MK-0859, , PRT054021, , blufomedil, bufomedil, Buflor AbZ, AbZ brand of buflomedil hydrochloride, Buflor-POS, Ursapharm brand of buflomedil hydrochloride, Buflor-Puren, Alpharma brand of buflomedil hydrochloride, Buflorhexal, Hexal brand of buflomedil hydrochloride, Buflomedil Heumann, Heumann brand of buflomedil hydrochloride, buflomedil hydrochloride, Buflomedil Lindo, Lindopharm brand of buflomedil hydrochloride, buflomedil pyridoxal phosphate, Buflomedil Stada, Stadapharm brand of buflomedil hydrochloride, buflomedil von ct, ct-Arzneimittel brand of buflomedil hydrochloride, Buflomedil-ratiopharm, ratiopharm brand of buflomedil hydrochloride, Fonzylane, Lafon brand of buflomedil hydrochloride, LL 1656, Loftyl, Bufedil, Lofton, Abbott brand of buflomedil hydrochloride, Sinaxis, Hosbon brand of buflomedil hydrochloride, Buflor 1A Pharma, 1A brand of buflomedil hydrochloride, , Folic Acid, Vitamin M, Pteroylglutamic Acid, Folate, Folvite, Folacin, , Hydrochlorothiazide, HCTZ, Dichlothiazide, Dihydrochlorothiazide, HydroDIURIL, Oretic, Sectrazide, Esidrix, Esidrex, Hypothiazide, , inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-

piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27, , voglibose, Basen, , Trapidil, Trapymine, Rocornal, , desdiethyltrapidil, N-dediethyltrapidil, desdiethyl-trapidil, , certoparin, certoparin sodium, Mono-Embolex, Novartis brand of certoparin sodium, Alphaparin, Grifols brand of certoparin sodium, , glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxyglimepiride, hydroxy-glimepiride, , Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356, , taspoglutide, , miti-glinide, KAD 1229, KAD-1229, , transcatheter aortic valve implantation, , sibutramine, Meridia, mono-desmethylsibutramine, BTS 54 524, BTS-54524, BTS 54524, Reductil, di-desmethylsibutramine, didesmethylsibutramine, (R)-DDMS, sibutramine hydrochloride, , saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , eplerenon, Inspra, CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100, , SYR 322, SYR322, SYR-322, , benfluramate, benfluorex maleate, SE 780, 780 SE, JP 992, Mediator trade name of benfluorex hydrochloride, Biopharma brand of benfluorex hydrochloride, Modulator trade name of benfluorex hydrochloride, Servier brand of benfluorex hydrochloride, S 780, benfluorex hydrochloride, 1-(2-trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl, , Coronary Artery Bypass, Coronary Artery Bypasses, Coronary Artery Bypass Surgery, Aortocoronary Bypass, Aortocoronary Bypasses, Coronary Artery Bypass Grafting, CABG, AR C69931MX, AR-C69931MX, , Carotid Endarterectomy, Carotid Endarterectomies, , Chlortalidone, Phthalamidine, Chlorphthalidolone, Oxodoline, Thalitone, Hygroton, , dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798, , docetaxol, Taxoltere metro, Taxotere, NSC 628503, RP 56976, RP-56976, ebselen, PZ 51, PZ-51, RP 60931, DR 3305, DR-3305, , Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide, , Exercise Therapy, Exercise Therapies, , Gene Therapy, DNA Therapy, Somatic Gene Therapy, , Ginkgo biloba, Ginkgo bilobas, Ginko, Ginkos, Ginkgo, Ginkgos, Gingko, Gingkos, Maidenhair Tree, Maidenhair Trees, Ginkgo biloba, Ginkgo bilobas, Ginkgophyta, Ginkgophytas, , Lacipil, Lacimen, Caldine, Motens, GR 43659X, GR-43659X, , olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec, , h5G1.1-scFv, pexelizumab, , Dalteparin, Tedelparin, Kabi-2165, Kabi 2165, Kabi2165, Fragmin, Fragmine, Dalteparin Sodium, FR-860, FR 860, FR860, , efegatran, Me-Phe-Pro-Arg-H, D-methyl-phenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efegatran sulfate, , etofibrate, Lipo-Merz, Merz brand of etofibrate, Tricerol, Armstrong brand of etofibrate, etofibrate hydrochloride, , simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259, , ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, , primary ballon angioplasty, primary PTCA, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus, , Gliclazide, Glyclazide, Gliklazid, Diamicon, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide, , Qnexa, Zontivity, SCH 530348, SCH530348, SCH-530348, , MDX-1106, ONO-4538, BMS-936558, Opdivo, lambrolizumab, Keytruda, MK-3475, , MDX-CTLA-4, Yervoy, DX 010, MDX010, MDX-010, , Iressa, ZD1839, ZD 1839, , Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican, , pertuzumab, Perjeta, Omnitarg, ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-DM1 conjugate, T-DM1 cpd, trastuzumab emtansine, huN901-DM1, Kadcyca, Avastin, , gemcitabine, dFdCyd, 2'-deoxy-2'-difluorocytidine, gemcitabine hydrochloride, LY 188011, LY-188011, Gemzar, , Toremifene, Toremifene Citrate, Toremifene Citrate (1:1), Fareston, FC-1157a, FC 1157a, FC1157a, , Xeloda, , Cisplatin, cis-Diamminedichloroplatinum(II), Platinum Diamminodichloride, cis-Platinum, cis Platinum, Dichlorodiammineplatinum, cis-Diamminedichloroplatinum, cis Diamminedichloroplatinum, cis-Dichlorodiammineplatinum(II), NSC-119875, Platino, Platinol, Biocisplatinum, Platidium, , ICI 182780, ICI-182780, ZM 182780, ZM-182780, Faslodex, , palbociclib, Ibrance, PD 0332991, PD0332991, PD-0332991, anastrozole, anastrazole, ICI D1033, ZD-1033, Zeneca ZD 1033, ZD1033, Arimidex, letrozole, Femara, Fmara, CGS 20267, CGS-20267, Aminoglutethimide, Cytadren, Orimeten, formestane, 4-hydroxyandrostenedione, 4-OHA, Lentaron, CGP-32349, CGP 32 349, CGP 32349, , exemestane, FCE 24304, FCE-24304, Aromasil, Aromasin, Aromasine, , Fadrozole, CGS-16949A, CGS 16949A, CGS16949A, Fadrozole Hydrochloride, Fadrozole Monohydrochloride, CGS 020286A, CGS020286A, CGS-020286A, FAD 286, FAD286, FAD-286, , Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox, ixabepilone, BMS247550, BMS-247550, BMS 247550, Herceptin, Torisel, CCI 779, CCI-779, , alirocumab, REGN727 monoclonal antibody, monoclonal antibody REGN727, SAR236553, Praluent, , AMG 145, evolocumab, AMG-145, Repatha, Medroxyprogesterone Acetate, Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17 Acetate, Depo-Medroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, Curretab, Cycrin, Depo-Provera, Depo Provera, DepoProvera, Farlutal, Perlutex, Provera, Veramix, Clinovir, Gestapuran, sorafenib, sorafenib N-oxide, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methanamide-4-methylbenzenesulfonate, BAY 545-9085, BAY-545-9085, sorafenib tosylate, BAY 43-9006, Nexavar, , entinostat, SNDX-275, MS 27-275, MS-275, MS 275, MS-27-275, B 1939, B-1939,

E 7389, E-7389, Halaven, NSC 707389, NSC707389, NSC-707389, B 1793, B-1793, ER-086526, ER086526, ER 086526, ER-86526, , Abraxane, vinorelbine, 5'-nor-anhydrovinblastine, Navelbine, vinorelbine tartrate, KW 2307, KW-2307, , intensive treatment, tighter control of blood pressure, low target blood pressure, strict blood pressure control, intensified blood-pressure control, IMC C225, IMC-C225, MAb C225, C225, Erbitux, , Tarceva, CP 358774, CP-358774, OSI-774, Inlyta, AG 013736, AG013736, AG-013736, , TKI 258, TKI258, TKI-258, dovitinib, CHIR 258, CHIR258, CHIR-258, , GW 786034B, GW786034B, GW-786034B, GW 780604, GW780604, GW-780604, Votrient, , Sutent, SU 11248, SU11248, SU-11248, SU011248, SU 011248, SU-011248, , D2E7 Antibody, Humira, Cimzia, Cimzias, CDP870, CDP870s, CDP 870, CDP 870s, , TNF Receptor Type II-IgG Fusion Protein, TNF Receptor Type II IgG Fusion Protein, Enbrel, Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein, Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein, TNFR-Fc Fusion Protein, TNFR Fc Fusion Protein, TNR-001, TNR001, TNR 001, TNT Receptor Fusion Protein, TNTR-Fc, , Simponi, , MAb cA2, Monoclonal Antibody cA2, Remicade, , Interleukin 1 Receptor Antagonist Protein, Urine-Derived IL1 Inhibitor, Urine Derived IL1 Inhibitor, IL1 Febrile Inhibitor, Urine IL-1 Inhibitor, IL-1Ra, Anril, Kineret, Anakinra, , tocilizumab, atlizumab, Actemra, , Rituxan, MabThera, Zytux, Rituximab, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, IDEC C2B8 Antibody, IDECC2B8 Antibody, IDEC-C2B8, IDEC C2B8, IDECC2B8, GP2013, Rituxan, , tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550, , durvalumab, Imfinzi, MPDL3280A, Tecentriq, RG7446, RG-7446, , MTA, Pemetrexed Disodium, LY 231514, LY231514, LY-231514, Alimta, , rolofylline, KW 3902, KW-3902, MK 7418, MK7418, MK-7418, , BG 9928, BG-9928, BG9928, BIO 4683, BIO4683, BIO-4683, BIO 5770, BIO5770, BIO-5770, BIO 8170, BIO8170, BIO-8170, BIO 9002, BIO9002, BIO-9002, tonapofylline, BIO 7505, BIO7505, BIO-7505, , Invokana, , BI 10773, BI10773, BI-10773, Jardiance, , dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148, , avelumab, MSB0010718C, , Xalkori, PF-02341066, PF02341066, PF 02341066, , BAY 94-8862, finerenone, , AZD 2281, AZD2281, AZD-2281, AZD221, Lynparza, , 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, niraparib hydrochloride, MK 4827, MK4827, MK-4827, , BMN 673, , 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, ABT 888, ABT888, ABT-888, , bococizumab, , CH5424802, alectinib, RO5424802, , ceritinib, Zykadia, LDK378, , AP26113, brigatinib, , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima, , imetelstat, motesanib, motesanib diphosphate, AMG 706, AMG706, AMG-706, , aflibercept, VEGF Trap-Eye, VEGF Trap - regeneron, VEGF-Trap, AVE 005, AVE005, AVE-005, Zaltrap, ZIV-aflibercept, AVE 0005, AVE0005, AVE-0005, eylea, , osimertinib, Tagrisso, , rucaparib, AG 014699, AG014699, AG-014699, PF-01367338, , cabozantinib, Cometriq, XL 184, XL184 cpd, XL-184, BMS 907351, BMS907351, BMS-907351, , abemaciclib, LY2835210, LY2385219, Verzenio, ribociclib, LEE011, , vemurafenib, Zelboraf, R05185426, RG7204, RG-7204, PLX4032, PLX 4032, , ticilimumab, CP 675, P675 cpd, CP-675, CP-675,206, CP-675206, CP675206, CP 675206,

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.